6月11日 - ** Enliven Therapeutics ELVN.O 在盘后交易中下跌2.7%，报39.28美元，此前该公司宣布了股权融资计划
** 这家生物制药公司启动了 (link) 的2.5亿美元融资计划，包括股票和预先注资的认股权证
** 周四，ELVN股价收涨9.1%，报40.36美元，此前其白血病药物ELVN-001在 (link) 试验中展现出令人鼓舞的早期结果
** 这家总部位于科罗拉多州博尔德的公司流通股为6,090万股，市值达25亿美元
** 截至收盘，该股年内累计涨幅达162%
** 据LSEG数据显示，全部12位分析师均给予该股“强烈买入”或“买入”评级；目标价中位数为59.50美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.